For research use only. Not for therapeutic Use.
Devimistat ( CPI-613 ) is a lipoate analogue that inhibits mitochondrial enzymes pyruvate dehydrogenase ( PDH ) and α-ketoglutarate dehydrogenase in NCI-H460 cell line and interferes with mitochondrial metabolism in tumor cells. CPI-613 can induce apoptosis of pancreatic cancer cells.
| Catalog Number | I005683 |
| CAS Number | 95809-78-2 |
| Synonyms | CPI613;CPI 613 |
| Molecular Formula | C₂₂H₂₈O₂S₂ |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| Solubility | 10 mM in DMSO |
| Storage | 2-8°C |
| IUPAC Name | 6,8-bis(benzylsulfanyl)octanoic acid |
| InChI | InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24) |
| InChIKey | ZYRLHJIMTROTBO-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2 |
| Reference | </br>1:Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D/’Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B.Lancet Oncol. 2017 May 8. pii: S1470-2045(17)30314-5. doi: 10.1016/S1470-2045(17)30314-5. [Epub ahead of print] PMID: 28495639 </br>2:A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J.PLoS One. 2016 Oct 12;11(10):e0164244. doi: 10.1371/journal.pone.0164244. eCollection 2016. PMID: 27732654 Free PMC Article</br>3:Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613. Lee KC, Maturo C, Perera CN, Luddy J, Rodriguez R, Shorr R.Ann Transl Med. 2014 Sep;2(9):91. doi: 10.3978/j.issn.2305-5839.2014.05.08. PMID: 25405166 Free PMC Article</br>4:A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.Clin Cancer Res. 2014 Oct 15;20(20):5255-64. doi: 10.1158/1078-0432.CCR-14-1019. Epub 2014 Aug 27. PMID: 25165100 Free PMC Article</br>5:Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism. Lee KC, Shorr R, Rodriguez R, Maturo C, Boteju LW, Sheldon A.Drug Metab Lett. 2011 Aug;5(3):163-82. PMID: 21722089 |
